Developing CAR Treg for Treating Autoimmune Disease
演讲题目:Developing CAR Treg for Treating Autoimmune Disease
Li Zhou, PhD, is VP of Cell Engineering at Txcell in France. TxCell is dedicated to the developing CAR-Treg therapy for the treatment of autoimmune diseases. Under his leadership, the team quickly established a diversed CAR-Treg based portfolio for treating autoimmune disease and for prevention of organ transplant rejection. Prior to this, he was Chief Scientific Officer and Director of research at ZMKS International Cancer Therapy Biotechnologies Co., LTD in developing various CAR-T programs for solid tumor and blood caner. Before this, he was a lab head in Novartis Biologics Center in Cambridge working on developing bispecific therapeutics and CAR-T therapies in collaboration with Dr Carl June at UPenn. He led a number of CAR-T programs including CAR-T CD22 to treat CAR-T CD19 relapse due to antigen negative escape, and Mesothelin CAR T for solid tumor. Top candidates are currently in clinical development at Novartis. He also led the program on developing regulatable CAR-T and achieved proof of concept in the animal model.